🇪🇸 Spain Country × Condition
colorectal cancer Clinical Trials in Spain
Active clinical trials for colorectal cancer with research sites in Spain. All data sourced live from ClinicalTrials.gov — updated daily.
Active Trials: 5 // Recruiting: 5 Phases: Phase 2 // Updated: Daily
Total Trials
5
Recruiting Now
5
Country
🇪🇸 Spain
Active Trials in Spain (5)
NCT05346757
Recruiting
Validation of a microRNA-based Fecal (miRFec) Test for Colorectal Cancer Screening, Surveillance and Diagnosis
Enrollment
5,390 pts
Country
🇪🇸 Spain
Fundacion Clinic per a la Recerca B...
View Trial → NCT06452745
Recruiting
Early Diagnosis of Colorectal Cancer Based on a Non-invasive Metabolomics Profile
Enrollment
2,000 pts
Country
🇪🇸 Spain
Institut Investigacio Sanitaria Per...
View Trial → NCT03957902 Phase 2
Recruiting
Assessment of Direct Biomarkers of Aspirin Action to Develop a Precision Chemoprevention Therapy of Colorectal Cancer
Enrollment
60 pts
Country
🇪🇸 Spain
Instituto de Investigación Sanitari...
View Trial → NCT07189312
Recruiting
Multi-scale Spatio-Temporal Analysis of Research Data
Enrollment
15 pts
Country
🇪🇸 Spain
Universidad de Granada
View Trial → NCT04120935
Recruiting
ALFAOMEGA Master Observational Trial
Enrollment
3,000 pts
Country
🇪🇸 Spain
IFOM ETS - The AIRC Institute of Mo...
View Trial → Frequently Asked Questions
How many colorectal cancer clinical trials are active in Spain?
There are currently 5 active clinical trials for colorectal cancer with sites in Spain, of which 5 are actively recruiting patients.
How can I join a colorectal cancer clinical trial in Spain?
To join a colorectal cancer clinical trial in Spain, select a recruiting trial below and check the eligibility criteria. Contact the trial's principal investigator or the listed site in Spain directly. All trials listed here are sourced from ClinicalTrials.gov, the official U.S. registry of clinical studies.
What phases are colorectal cancer trials in Spain?
Active colorectal cancer trials in Spain span Phase 2. Phase I trials test safety, Phase II test efficacy, and Phase III compare against standard treatments in larger patient populations.